Efficacy and metabolic outcomes of switching from an INSTI-based triple-drug regimen to dolutegravir/lamivudine in treatment-experienced HIV-1-infected patients: a 48-week real-world study

Article

Author: Li, Qisui ; Zhang, Wei ; Yuan, Jing ; Deng, Changgang

BACKGROUND:

Real-world data on switching from INSTI-based triple therapy to DTG/3TC in the Chinese population are lacking.

METHODS:

This retrospective study included 214 treatment-experienced patients with HIV from Chongqing Public Health Medical Center (2021-2022) on an INSTI-based triple-drug regimen for ≥6 months who switched to DTG/3TC for >12 months. Patients with pre-existing metabolic diseases were excluded. Participants were categorized: INSTI+TAF-free (n = 100, prior TDF/AZT/ABC), INSTI+TAF (n = 56, prior BIC/FTC/TAF), and INSTI+TAF+COBI (n = 58, prior EVG/c/FTC/TAF). Virological, immunological, and metabolic parameters were assessed at weeks 24 and 48.

RESULTS:

The INSTI+TAF+COBI group was significantly older (p=0.000). Virological suppression rates (<50 copies/mL) were high at switch (93%, 85.7%, 91.4%). The INSTI+TAF+COBI group had lower eGFR and higher TG, TC, HDL, and LDL at baseline (p < 0.05). After switching, virological suppression remained high (≥90%) at weeks 24 and 48. CD4+ T-cell increases showed no significant intergroup differences. Metabolic changes differed: TC changes were 0.57 mmol/L (IQR: -0.19-0.91) in INSTI+TAF-free, -0.09 mmol/L (-0.47-0.71) in INSTI+TAF, and -0.25 mmol/L (-0.99-0.33) in INSTI+TAF+COBI. LDL changes were 0.23 mmol/L (-0.23-0.67), -0.15 mmol/L (-0.39-0.01), and -0.18 mmol/L (-0.71-0.10), respectively. TC and LDL changes differed significantly among groups (p < 0.05).

CONCLUSION:

Switching to DTG/3TC maintained virological suppression and stable immunological outcomes. Patients previously on TAF-containing regimens demonstrated greater metabolic benefits than those on TAF-free regimens, possibly related to baseline TDF effects, requiring further confirmation.

31 Dec 2026·HIV Research & Clinical Practice

Successful initiation of fully parenteral antiretroviral therapy in a treatment-naïve person with HIV-1 infection and intestinal failure

Article

Author: Sram, Krystof ; Lhotan, Jakub ; Jilich, David ; Sevela, Stanislav ; Rozsypal, Hanus

INTRODUCTION:

In patients with severe surgical and gastrointestinal complications, standard oral combination antiretroviral therapy (ARV) may be temporarily impossible. Long-acting cabotegravir/rilpivirine (CAB/RPV LA) is approved for virologically suppressed individuals pretreated with oral therapy, but data on its use in treatment-naïve, critically ill patients with absent enteral absorption are extremely limited.

CLINICAL PRESENTATION:

We report a 26-year-old male admitted with fulminant hypertriglyceridaemic necrotizing pancreatitis complicated by abdominal compartment syndrome, multiple laparotomies, open abdomen with enteric fistulae, short bowel syndrome type I, chronic intestinal failure requiring parenteral nutrition, portal vein thrombosis, and prolonged intensive care. HIV-1 infection was diagnosed early (HIV RNA 5,000 copies/mL; CD4+ 780 cells/µL). Within three months, HIV RNA rose to 320,000 copies/mL and CD4+ declined to 570 cells/µL. Given absent gastrointestinal passage, standard ARV was initially deferred, but rapid virological rebound necessitated urgent treatment. An off-label fully parenteral regimen was initiated: intravenous zidovudine (AZT) with intramuscular CAB/RPV LA. Therapy was well tolerated alongside surgery, parenteral nutrition, antimicrobials, and anticoagulation. HIV RNA decreased to <20 copies/mL within 65 days and remained suppressed, with CD4+ recovery. Intravenous AZT was discontinued after 35 days, and CAB/RPV LA continued as maintenance during recovery and home parenteral nutrition.

DISCUSSION:

Fully parenteral ARV, including CAB/RPV LA, may provide a safe and effective bridge to durable viral suppression in patients with absolute contraindications to oral therapy, warranting further evaluation.

01 Oct 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Mechanism of terahertz low-frequency vibrational spectral absorption in zidovudine and its derivatives under active excitation

Article

Author: Yang, Weifang ; Tu, Shan ; Li, Xinru ; Deng, Jiamei ; Xiao, Heng ; Li, Yanxin ; Yang, Hu ; Chen, Yun

This study utilized terahertz time-domain spectroscopy (THz-TDS) combined with dispersion-corrected density functional theory (DFTD3, Grimme' s D3 dispersion correction) to systematically examine the absorption characteristics of adenosine, vidarabine, and zidovudine in the 0.3 to 2.0 THz range. Experimental and simulated results showed excellent agreement, collectively revealing the characteristic absorption spectra of zidovudine and its derivatives in this frequency region. Potential energy distribution (PED) analysis was applied to identify vibrational modes: adenosine primarily exhibits dihedral angle torsions, whereas vidarabine and zidovudine involve both dihedral angle torsion and out-of-plane bending vibrations. Weak interactions were visualized using the interaction region indicator (IRI) and the independent gradient model based on Hirshfeld partition (IGMH) methods, which helped identify the locations and types of these interactions. Compared to the holistic perspective provided by IRI, the IGMH approach allows precise characterization of weak interactions between specific molecular pairs. Results indicate that van der Waals (vdW) interactions dominate the weak interactions in all three molecules. Energy decomposition analysis based on forcefields (EDA-FF) further revealed that attractive electrostatic and dispersion contributions are largely counterbalanced by steric effects. These findings confirm that THz spectroscopy can effectively differentiate isomers and serve as a key tool for elucidating intermolecular interactions and the associated THz absorption mechanisms.

News (Medical) associated with Zidovudine

20 Jan 2026

·www.biopharmadive.com

GSK to buy Rapt in $2.2B deal for food allergy drug

Dive Brief:GSK on Tuesday said its agreed to buy Rapt Therapeutics for $2.2 billion, gaining access to a drug that promises to help a wider population of patients avoid allergic reactions to food.The medicine, ozureprubart, targets the immunoglobulin E, or IgE antibodies that are produced when a patients immune system overreacts after encountering allergens. Once released, the IgE antibodies help trigger allergic reactions that can sometimes be deadly for patients.Ozureprubart is currently in Phase 2b testing, and Rapt believes it has the potential to be administered every eight to 12 weeks, instead of the two-to-four week regimens currently used for Roche and Novartis Xolair. The company also expects the drug to be used by a bigger pool of patients, including those with high levels of IgE or a body weight that makes them ineligible to take Xolair.Dive Insight:The Rapt deal offers the potential of another blockbuster to beef up the British drugmakers retrenched pipeline. Former CEO Emma Walmsley, who had run GSK since April 2017, stepped down at the end of last year after streamlining the business and focusing it more on oncology and innovative medicines.Through much of Walmsleys tenure, GSK faced pressure from investors who believed that the company was underperforming rivals. Traditionally a powerhouse in vaccines, GSK opted not to develop its own shot during the COVID-19 pandemic and partnerships with other vaccine makers stumbled. Meanwhile, the maker of AZT faced pressure on its pioneering HIV business as patent losses loomed.The last year, however, saw a turnaround for GSK. The companys shares have jumped about 42% over the last 12 months in New York trading, far outpacing the 26% climb in the S&P 500 Pharmaceuticals Index. Major drug approvals helped, including wins for a multiple myeloma medicine and a twice-yearly asthma treatment billed as a potential change in standard of care.And just this month, GSK announced promising results for an experimental hepatitis B treatment. The companys chief scientific officer, Tony Wood, highlighted that drug recently when he told investors GSK aims to launch 15 medicines with peak sales potential of more than $2 billion each in the coming years.The Rapt drug fits into that vision for future blockbusters. In the U.S. alone, more than 17 million people suffer from food allergies, causing some 3 million visits to hospitals and emergency care centers. Effective drugs to prevent allergic reactions could compete in a market worth $10 billion or more, Jefferies analyst Michael Leuchten wrote in a note to clients.Ozureprubart may end up being a multi-blockbuster opportunity for food allergy treatment as well as other indications linked to IgE, Leerink Partners analyst Thomas Smith wrote in a separate note. The deal is a strong strategic fit for GSK, he added.For Rapt, the GSK deal caps an unlikely turnaround. The company abandoned its previous lead drug amid safety concerns and later had to cut staff twice. As late as July of last year, Rapt shares were trading below $8. But promising early results for ozureprubart, licensed from China in late 2024, changed its fortunes. On Tuesday, Rapt shares soared close to the GSK offer price of $58.The companies expect the deal to close in the first quarter of this year. '

Phase 2VaccineAcquisitionPhase 3Executive Change

30 Dec 2024

·pharma.economictimes.indiatimes.com

'Breakthrough of the Year' drug for HIV care

New Delhi: Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug Administration ( FDA ) approving lenacapavir, a new prototype medication. It uses a unique mechanism of twice-yearly injections to treat individuals with multidrug-resistant HIV. The development of lenacapavir by Gilead Sciences has been described by the journal Science as the 2024 Breakthrough of the Year. It noted that it was "a pivotal step toward diminishing HIV/AIDS as a global health crisis." The introduction of lenacapavir is potentially a major step forward in the treatment of HIV/AIDS globally. It could help achieve UN Sustainable Development Goal 3 which sets the target of eliminating HIV/AIDS as a public health threat and moving towards a sustainable HIV response beyond 2030. The breakthrough comes at a time when HIV/AIDS remains a formidable challenge in global public health since it was discovered in the early 1980s. Initially identified in the United States, HIV/AIDS has since claimed more than 42 million lives worldwide and infected more than 88 million people. There were 39.9 million people living with AIDs globally at the end of 2023. While advancements in antiretroviral therapy (ART, a combination of HIV medicines that treats people infected with the virus) have transformed the management of HIV, it continues to pose significant challenges, particularly for individuals with multidrug-resistant strains of the virus. HIV originated from zoonotic transmission, likely jumping from non-human primates to humans in Central and West Africa in the early 20th century. However, it was not until 1983 that French researchers identified the virus responsible for what later became known as AIDS (acquired immunodeficiency syndrome). This marked the start of a global fight against a virus that devastates the immune system, leaving individuals vulnerable to opportunistic infections and certain cancers. Antiretroviral therapy, first introduced with the FDA's approval of AZT in 1987, was a turning point in HIV treatment. Over 50 antiretroviral drugs are now FDA-approved, offering a range of options to manage the virus effectively. Despite these advances, HIV remains incurable, and many patients face challenges such as drug resistance, requiring new therapeutic innovations. To understand the impact of HIV, it helps to compare it with the recent COVID-19 pandemic. COVID-19, largely preventable through vaccines and treatments, differs from AIDS, which remains incurable and can only be managed with antiretroviral therapies. COVID-19 spread rapidly, causing over seven million deaths worldwide in a short time. Respiratory viruses like SARS-CoV-2 that caused COVID-19 are well-studied, and the targets of vaccine development well characterised. In contrast, HIV's high mutation rate, integration into human DNA, and long latency period have made vaccine development extremely challenging. Unlike COVID-19, which mainly causes acute illness, HIV gradually weakens the immune system, leading to chronic vulnerability to infections like tuberculosis, resulting in far higher mortality rates. Efforts to combat HIV are further complicated by stigma and discrimination, particularly among marginalised communities. It has been estimated that sub-Saharan Africa, which accounts for 15 per cent of the global population, has two-thirds of the people living with HIV. About 4,000 teen girls and young women are newly infected with HIV every week (2022 figures). In this context, the FDA's approval of lenacapavir, a first-in-class drug designed for individuals with multidrug-resistant HIV, is indeed a breakthrough. Lenacapavir's efficacy was demonstrated through extensive clinical trials conducted globally, including in many countries in Latin America, South Africa, Thailand and the United States. The details of the clinical trials study (called PUPOSE 2) conducted by Gilead state, "Lenacapavir was highly effective at reducing HIV infections among trial participants: 99.9% of participants did not acquire HIV in the lenacapavir group, with two incident cases among 2,179 participants (0.10/100 person-years, 95% CI, 0.01 to 0.37)." This, the study claimed, was despite reported high levels of sexual behavior, chemsex and sexually transmitted infections observed among PURPOSE 2 participants. The trials highlighted its potential to significantly reduce viral loads, particularly in patients who had exhausted other treatment options. Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. The procedure for administering lenacapavir involves an initial oral loading dose, followed by subcutaneous injections every six months. Lenacapavir works by targeting the HIV capsid, a protein shell that protects the virus's genetic material. The drug is not a standalone therapy and must be used in combination with other antiretroviral medications to ensure comprehensive viral suppression. Because of its innovative mechanism and extended dosing schedule it has been described as a pathbreaking advancement in HIV care and is being heralded as an early vaccine-like innovation in HIV treatment, providing extended viral suppression that minimises daily treatment burdens. This simplified regimen improves adherence and reduces the risk of treatment failure due to missed doses. However, a major challenge in the widespread use of lenacapavir particularly in low- and middle-income countries which have high loads of HIV infections is mainly due to its current cost. Early pricing has indicated significant disparities, which have led to calls for subsidies and international collaboration to make the drug accessible to those who need it most. Already, the Global Fund to Fight AIDS has joined hands with several other foundations for a coordinated effort to provide affordable and equitable access to the twice-yearly injectable drug. This would be subject to "regulatory approval from the U.S. Food and Drug Administration, relevant national pharmaceutical regulators, and a recommendation from the World Health Organization (WHO)." However, the FDA has now approved the drug. Lenacapavir has also been approved in several countries to treat adults who have multiple drug-resistant HIV, to be used along with other antiretroviral drugs. There are indications that the drug can also prevent new HIV infections. In October this year, Gilead announced that it has "signed non-exclusive, royalty-free voluntary licensing with six pharmaceutical companies to manufacture and supply high-quality, low-cost versions of lenacapavir for HIV prevention for 120 primarily low- and lower-middle-income countries." While the development of lenacapavir is a major innovative step forward in the fight against HIV, it also underscores the importance and need for continued research for more efficacious therapies against HIV including anti-HIV vaccine innovation, and equitable healthcare policies. The fight against HIV continues, but lenacapavir offers promise for improved management of the infection. (360info.org) GSP

Drug ApprovalVaccineClinical StudyImmunotherapy

15 Oct 2024

·www.prnewswire.com

WARBURG PINCUS STRENGTHENS ITS EUROPEAN BUSINESS AND GLOBAL HEALTHCARE GROUP WITH TWO NEW SENIOR ADVISERS

Seasoned industry experts will advise Warburg Pincus on new investments and drive value creation across its portfolio companies LONDON and BERLIN, Oct. 15, 2024 /PRNewswire/ -- Warburg Pincus, a leading global growth investor, today announced the appointment of Dr. Francesco Granata and Dr. Axel Herberg as Senior Advisers working with its European business and global healthcare group. Dr. Granata and Dr. Herberg will support Warburg Pincus in the identification and evaluation of new potential investment opportunities across Europe for its funds, and they bring deep expertise and connectivity within the pharmaceutical, life sciences, medical device and healthcare sectors. The senior adviser appointments follow the recent announcement of Enovo Life Sciences, a new life sciences platform institutionally capitalized by funds advised by Warburg Pincus and led by life sciences industry veterans, Mario Philips and Roel Gordijn. These announcements demonstrate the continued momentum in Warburg Pincus's European business. Jake Strauss, a Managing Director in the global healthcare group, was recently announced as head of the firm's European healthcare efforts and Tobias Weidner, recently joined the firm as a Managing Director leading industrials in Europe. Recent European investments include Aztec, Specialist Risk Group and Epassi. Dr. Herberg brings wide-ranging experience as an operator and investor. He is a member of various supervisory boards and is an active entrepreneur. He joined the Gerresheimer Group in 1992 and developed the company to a leading systems and solutions provider to the pharma and biotech industries and is currently Chairman of the Supervisory Board. Between 2010 and 2017, Dr. Herberg was a Partner at Blackstone, responsible for the private equity business in the German-speaking regions of Europe. Dr Herberg currently sits on the boards of Gerresheimer, Axplora, and Vetter Pharma. Dr. Granata has more than 40 years of experience in the pharmaceuticals and biotechnology industries. He was Executive Vice President and member of the Executive Committee at Biogen Idec; served as Group Vice President at Schering-Plough, and President of Schering-Plough Europe and Canada; and held various senior management positions at Pharmacia, Dompé Biotech, and Pfizer. He currently sits on the Boards of Italfarmaco and GreenBone Ortho. He is General Partner and co-founder of Venture Capital firm 3B Future. Jake Strauss, Managing Director at Warburg Pincus, said, "We are excited to be working with Francesco and Axel. They bring decades of invaluable experience and strong networks across Europe that will further enhance our ability to identify attractive investment opportunities for our funds where we can partner with management teams, entrepreneurs, and families to accelerate growth. Their experience will also be invaluable to our existing portfolio companies in allowing them to navigate the complex macroeconomic and technological drivers of change that are transforming their industries." Dr Axel Herberg said, "I am looking forward to working with the exceptional team at Warburg Pincus. The firm's strong reputation, deep sector expertise and recent growth in Europe, make this an exciting time to work with the European team." Dr Francesco Granata said, "Warburg Pincus has a long history of successfully partnering with founders and management teams and bringing deep expertise to help businesses build long-term sustainable growth. I look forward to working together to identify exciting new businesses and strong management teams driving innovation, technological change and improved patient outcomes across the healthcare sector." Funds advised by Warburg Pincus have been among the leading global growth investors in Europe and were one of the first to invest in Europe in 1983. In Europe, the Warburg Pincus funds have invested more than $14 billion in over 125 companies across more than 20 European countries. Warburg Pincus funds have invested over $18 billion in more than 189 innovative healthcare and life sciences companies around the world, including Bausch + Lomb, Ensemble Healthcare Partners, Global Healthcare Exchange, Modernizing Medicine, and Sotera Health. The firm has also notably been active in the European healthcare market including recent investments by the funds in Polyplus, Simtra BioPharma Solutions, Norstella and the START Center for Cancer Research. About Warburg Pincus Warburg Pincus LLC is a leading global growth investor. The firm has more than $83 billion in assets under management. The firm's active portfolio of more than 225 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Since its founding in 1966, Warburg Pincus has invested more than $117 billion in over 1,000 companies globally across its private equity, real estate, and capital solutions strategies. The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information please visit . Follow us on LinkedIn. Media Contact Jenna Ward, Europe Communications Director M: +44 7570 844 338 E: [email protected] WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive Change

100 Deals associated with Zidovudine

External Link

KEGG	Wiki	ATC	Drug Bank
D00413	Zidovudine	J05AF01	DB00495

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	19 Mar 1987

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	United States	Glaxo Wellcome SA	31 Aug 2001
Pregnancy	Phase 3	Puerto Rico	Glaxo Wellcome SA	31 Aug 2001
Toxoplasmosis, Cerebral	Phase 1	United States	Glaxo Wellcome SA	31 Aug 2001
Acquired Immunodeficiency Syndrome	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001
Acquired Immunodeficiency Syndrome	Clinical	Puerto Rico	Glaxo Wellcome SA	31 Aug 2001
AIDS Dementia Complex	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001
AIDS-Related Complex	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001
AIDS-Related Complex	Clinical	Puerto Rico	Glaxo Wellcome SA	31 Aug 2001
HIV Seropositivity	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001
Kidney Failure, Chronic	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02737046 (CTgov)	Phase 2	Adult T-Cell Leukemia-Lymphoma	15	Pegylated Interferon-Alfa-2b+Interferon-Alfa-2b+Zidovudine+Belinostat	rsmntjgcqq = nhdqwelhba dgpstbjoma (vbxvkhoams, qdphksirxm - ohdokofjho) View more	-	10 Mar 2026
ASH2025	Not Applicable	Adult T-Cell Leukemia-Lymphoma	177	CHOP	qsmghhkdmz(stuekdeupc) = gcpogbesqa pfpokiloew (xbialibsmi ) View more	Negative	06 Dec 2025
NCT02737046 (ASH2025)	Phase 2	Adult T-Cell Leukemia-Lymphoma	15	AI-BEL (AZT/Interferon-α plus Belinostat)	lfkcctahax(ktyuacxkzk) = faaofwmidb ekxmbttgfi (xzfoejboia ) View more	Positive	06 Dec 2025
NCT03988452 (NADIA, Pubmed \| Lancet HIV)	Phase 3	HIV Infections Second line	465	Dolutegravir	brrgqmdqkm(ghngqbzoxi) = jweepwryvc lohughskgy (ahcjzsfuxc )	Positive	20 Apr 2022
				Ritonavir-boosted darunavir	brrgqmdqkm(ghngqbzoxi) = bzexzwwscz lohughskgy (ahcjzsfuxc )
NCT01818258 (IMPAACT P1092, CTgov)	Phase 4	Malnutrition \| HIV Infections	52	Zidovudine+Lamivudine+Lopinavir/Ritonavir (Severe Malnutrition)	dikpkkrozk(vmrvrhhebv) = uuvtvulqix syefvrjcod (ikbvfpemkk, xuitixcxjo - idvourcnhj) View more	-	12 Aug 2021
				Zidovudine+Lamivudine+Lopinavir/Ritonavir (Normal Nutrition/Mild Malnutrition)	dikpkkrozk(vmrvrhhebv) = eiunzpkorf syefvrjcod (ikbvfpemkk, coqyzasqrz - ybbwflzmvx) View more
NCT02369406 (Early Infant Treatment Study in Botswana, Pubmed \| Clin Infect Dis)	Phase 2/3	-	40	Nevirapine (NVP), Zidovudine (ZDV), and Lamivudine (3TC)	cidukfvipa(qayaicyvgc) = lgmbqiptly fzyofhdfgi (tkjuaqmvfq ) View more	Positive	01 Feb 2021
				Lopinavir-ritonavir (LPV-r)	cidukfvipa(raunjtmyeu) = wuwhbwpjrh lmppoxzual (tsxiacxgyv )
NCT01441063 (CTgov)	Phase 2	Multi-Centric Castleman's Disease	8	Tocilizumab (Tocilizumab Monotherapy)	jyfcvwgxvm = elkdkfnxzq kapjgdrbla (xwirozoikl, vvzgzeedtf - usfdsxxetk) View more	-	23 Jun 2020
				Tocilizumab (Tocilizumab Combination Therapy)	jyfcvwgxvm = psqewlslbu kapjgdrbla (xwirozoikl, shirslleim - ikawdbutnq) View more
NCT01386970 (CTgov)	Phase 4	HIV Infections	43	zidovudine+Combivir+lamivudine (HIV-negative)	uolwgjwyoj(msmdoiyqvt) = negvlyatax tzlcldkdea (poxxjntudb, suoirmtknh - lpxxbbwmau) View more	-	16 Mar 2020
				zidovudine+Combivir+lamivudine (HIV-infected)	uolwgjwyoj(msmdoiyqvt) = xcbnzrtund tzlcldkdea (poxxjntudb, mnkqwlwbbf - yhbwgwryzt) View more
NCT01964755 (CTgov)	Phase 2	Post-transplant lymphoproliferative disorder \| Acquired Immunodeficiency Syndrome \| Epstein-Barr virus associated Hodgkin's Lymphoma ... View more	6	Zidovudine+Leucovorin+Doxorubicin+hydroxyurea+Methotrexate+Rituximab	osxzcwahth = kojpupudzx nrukzwkfde (iuhqephowg, yksvigdcdi - gcqqgwtczo) View more	-	23 Sep 2019
NCT00102960 (CHER, CTgov)	Phase 3	HIV Infections	377	Zidovudine+Abacavir sulfate+Didanosine+Efavirenz+Lamivudine+Nevirapine+Lopinavir/Ritonavir	lhobmwdqcf = xmznunrbnk wfpttulzpl (hewbcbdhls, lbzrsdzvyi - zixwlchfwq)	-	30 Nov 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis